Ibogaine for Depression and Anxiety: What We Know So Far

Ibogaine is not an approved treatment for depression or anxiety, and it has not yet been tested in trials designed for those conditions alone. But when researchers have measured mood in people treated with ibogaine for trauma or addiction, the changes have been large: in a 2024 Stanford study of 30 veterans, depression symptoms fell by an average of 87% and anxiety by 81% one month after treatment. These results are encouraging, but they come from small, uncontrolled studies, and ibogaine carries medication interactions and cardiac risks that matter especially for people already taking antidepressants.

Key takeaways

• There are no clinical trials of ibogaine for depression or anxiety as the main condition yet.
• In the Stanford veterans study, depression fell by 87% and anxiety by 81% on average one month after treatment.
• People treated for opioid addiction have described lasting improvements in coping with stress and difficult emotions.
• Many antidepressants interact with ibogaine or affect the heart, so they must be reviewed and often tapered under medical supervision first.
• Ibogaine is not suitable for people with bipolar I disorder or a history of psychosis, and cases of mania after ibogaine have been reported.

What the research shows

Veterans with trauma and brain injury

The clearest data come from Stanford's study in Nature Medicine (2024). Thirty special operations veterans, many with PTSD, depression and anxiety, received ibogaine with magnesium at a clinic in Mexico. One month later, depression scores had fallen by an average of 87%, anxiety by 81% and PTSD symptoms by 88%. Nineteen of the 30 had previously had suicidal thoughts. We cover the full study in ibogaine for veterans with PTSD.

People treated for addiction

In a survey of 88 people treated with ibogaine for opioid use in Mexico, those who did well described persistent changes in their ability to tolerate painful feelings, their capacity to cope with stress and a reduction in unhealthy anger. A 2018 open-label series of 191 patients in St. Kitts, published in Frontiers in Pharmacology, tracked mood and craving during detox and reported reduced cravings with no significant adverse events at the doses used.

What these studies cannot tell us

All of these studies lack a placebo group, and most participants had depression alongside trauma or addiction, not on its own. We do not yet know how ibogaine compares with antidepressants, therapy or other treatments for depression, or how long the benefits last. Until controlled trials are done, ibogaine for depression should be considered experimental.

Why ibogaine might affect mood

Ibogaine and its long-acting metabolite, noribogaine, act on serotonin transporters and on kappa opioid receptors, both of which are involved in mood. Animal studies show ibogaine increases neurotrophic factors linked to neuroplasticity, and Stanford's brain recordings found changes in cortical activity associated with symptom improvement. Many patients also describe the experience itself, a long review of memories and relationships, as a turning point in how they see their past.

Antidepressants and ibogaine: an important warning

This is the most important safety point for people with depression:

• Several antidepressants raise ibogaine levels. Fluoxetine and paroxetine strongly inhibit the liver enzyme CYP2D6, which breaks down ibogaine, increasing exposure and cardiac risk.
• Many psychiatric medications prolong the QT interval, as ibogaine does. Combining them increases the risk of dangerous arrhythmias.
• Never stop medication on your own. Stopping antidepressants abruptly can cause withdrawal symptoms and a relapse of depression. Any taper must be planned with your prescribing doctor and our medical team, sometimes over several weeks.

Who should not receive ibogaine

• People with bipolar I disorder, a history of mania or a psychotic disorder. Cases of mania after ibogaine have been published.
• People in an acute suicidal crisis, who need immediate psychiatric care first.
• People with heart disease, a prolonged QT interval or electrolyte problems.

If you are thinking about suicide, seek help now: in the United States call or text 988; in Mexico call the Línea de la Vida at 800 911 2000.

How we approach mood at Ibogaine Center Cancún

Every candidate goes through a medical and psychiatric screening, a full medication review and a cardiac evaluation before acceptance. During treatment, a cardiologist is on site, with continuous EKG telemetry and one-to-one ACLS nursing. Afterwards, our 90-day aftercare plan focuses on integration and on connecting you with ongoing therapy at home. Learn more about heart safety and what the 7 days look like.

See how treatment works, what is included and who can apply in our ibogaine program for trauma and treatment-resistant depression.

Frequently asked questions

Can ibogaine cure depression?

No. Ibogaine is not a cure and is not approved for depression. Large improvements have been measured in veterans and in people treated for addiction, but there are no controlled trials for depression alone.

Do I need to stop my antidepressants before ibogaine?

Often yes, but only with medical supervision. Some antidepressants increase ibogaine levels or affect the heart. Your doctor and our team must plan any change, and it can take weeks.

Is ibogaine better than psilocybin or ketamine for depression?

They have not been compared directly. Psilocybin and ketamine have more research for depression specifically. Ibogaine is most studied for addiction and trauma and requires cardiac monitoring.

How long do the mood effects last?

The Stanford study measured one month. Patients often report longer benefits, especially with therapy and lifestyle changes afterwards, but long-term controlled data do not exist yet.

Can ibogaine help with anxiety?

Anxiety fell by 81% on average in the Stanford veterans study. As with depression, this comes from a small study without a control group.

References

• Cherian, K. N. et al. "Magnesium–ibogaine therapy in veterans with traumatic brain injuries." Nature Medicine, 2024.
• Davis, A. K. et al. "Subjective effectiveness of ibogaine treatment for problematic opioid consumption." Journal of Psychedelic Studies, 2017.
• Mash, D. C. et al. "Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes." Frontiers in Pharmacology, 2018.

Living with depression or anxiety that has not responded to treatment? Our medical team will review your history and medications confidentially and tell you honestly whether ibogaine is a safe option. Request your evaluation.